Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myelomaPotential for autocrine and paracrine networks

Experimental Hematology

Volumn 29, Issue 9, 2001, Pages 1076-1081

  Szczepek, Agnieszka J ^a   Belch, Andrew R ^a   Pilarski, Linda M ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ARTICLE; B LYMPHOCYTE; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD31; AUTOCRINE COMMUNICATION; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CLONE CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; PARACRINE COMMUNICATION; RECEPTORS, INTERLEUKIN-6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0034893680     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(01)00682-8     Document Type: Article

References (32)

1. Interleukin-6 and its receptor; ten years later
2. Interleukin-6 (IL-6) and its receptor; their role in plasma cell neoplasias
3. Gp130 in human myeloma/plasmacytoma
4. Gp130 cytokine family and bone cell
5. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma
6. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line
7. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
8. Increased production of interleukin-6 by T lymphocytes from patients with multiple myeloma
9. Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance
10. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo
11. Monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells
12. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors
13. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma
14. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma
15. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin
16. Persistent pre-switch clonotypic myeloma cells correlate with decreased survival; evidence for isotype switching within the myeloma clone
17. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma; alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44
18. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules
19. High frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase polymerase chain reaction
20. Characterization of osteoclast precursors in human blood
21. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member
22. Human myeloma cells express the CD38 ligand CD31
23. + cells in the blood of patients with multiple myeloma express CD19 and IgH MRNA and have patient-specific IgH VDJ gene rearrangements
24. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells
25. Impaired immune and acute-phase responses in interleukin-6-deficient mice
26. Defective inflammatory response in interleukin 6-deficient mice
27. Myeloma progenitors in the blood of patients with aggressive or minimal disease; engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice
28. Thalisomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
29. Bone marrow histology and serum β 2 microglobulin in multiple myeloma-a new prognostic strategy
30. Bone marrow biopsy in multiple myeloma; a clinical pathological study